{
  "first_published_at": "2010-08-09", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON090901", 
  "title": "Modafinil: European Medicines Agency recommends restricted use", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\", \"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\", \"Respiratory disease and allergy\"]}", 
  "_document_number": 191, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "neurology", 
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Modafinil: European Medicines Agency recommends restricted use</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The European Medicines Agency has recommended that the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy, and that it should no longer be used for the treatment of excessive sleepiness associated with obstructive sleep apnoea or chronic shift work sleep disorder.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Modafinil</strong> (Provigil) is a wakefulness-promoting agent.</p><p>The European Medicines Agency has recommended that the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy, and that it should no longer be used for the treatment of excessive sleepiness associated with obstructive sleep apnoea or chronic shift work sleep disorder.</p><p>On the basis of the available data, the Agency&rsquo;s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines only outweighed their risks in the therapeutic indication narcolepsy. For all other indications the Committee found that the risks outweighed the benefit shown in clinical trials. Therefore, the Committee concluded that all other indications should be withdrawn from the marketing authorisations of these medicines.</p><p><strong>Further information</strong> is available from the European Medicines Agency website <a href=\"http://www.ema.europa.eu/ema/index.jsp\">http://www.ema.europa.eu/ema/index.jsp</a></p><p>See also previous advice for modafinil from <a href=\"ssLINK/CON084779\" target=\"_blank\">Drug Safety Update March 2008</a>.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Aug 2010, vol 3 issue 1: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Modafinil</strong> (Provigil) is a wakefulness-promoting agent.</p><p>The European Medicines Agency has recommended that the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy, and that it should no longer be used for the treatment of excessive sleepiness associated with obstructive sleep apnoea or chronic shift work sleep disorder.</p><p>On the basis of the available data, the Agency&#8217;s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines only outweighed their risks in the therapeutic indication narcolepsy. For all other indications the Committee found that the risks outweighed the benefit shown in clinical trials. Therefore, the Committee concluded that all other indications should be withdrawn from the marketing authorisations of these medicines.</p><p><strong>Further information</strong> is available from the European Medicines Agency website <a href=\"http://www.ema.europa.eu/ema/index.jsp\">http://www.ema.europa.eu/ema/index.jsp</a></p><p>See also previous advice for modafinil from <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON084779\" target=\"_blank\">Drug Safety Update March 2008</a>.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Aug 2010, vol 3 issue 1: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-08-01", 
  "date_last_modified": "2010-09-17", 
  "_assets": [], 
  "_item_id": 191, 
  "summary": "", 
  "body": "Article date: August 2010\n\nModafinil (Provigil) is a wakefulness-promoting agent.\n\nThe European Medicines Agency has recommended that the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy, and that it should no longer be used for the treatment of excessive sleepiness associated with obstructive sleep apnoea or chronic shift work sleep disorder.\n\nOn the basis of the available data, the Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines only outweighed their risks in the therapeutic indication narcolepsy. For all other indications the Committee found that the risks outweighed the benefit shown in clinical trials. Therefore, the Committee concluded that all other indications should be withdrawn from the marketing authorisations of these medicines.\n\nFurther information is available from the European Medicines Agency website <http://www.ema.europa.eu/ema/index.jsp>\n\nSee also previous advice for modafinil from [Drug Safety Update March 2008](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON084779).\n\n \n\nArticle citation: Drug Safety Update Aug 2010, vol 3 issue 1: S1.\n"
}